Daniel R Malan

417 total citations
7 papers, 221 citations indexed

About

Daniel R Malan is a scholar working on Hematology, Genetics and Infectious Diseases. According to data from OpenAlex, Daniel R Malan has authored 7 papers receiving a total of 221 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Hematology, 3 papers in Genetics and 2 papers in Infectious Diseases. Recurrent topics in Daniel R Malan's work include Hemophilia Treatment and Research (4 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and HIV/AIDS Research and Interventions (2 papers). Daniel R Malan is often cited by papers focused on Hemophilia Treatment and Research (4 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (2 papers) and HIV/AIDS Research and Interventions (2 papers). Daniel R Malan collaborates with scholars based in South Africa, United States and Chile. Daniel R Malan's co-authors include Donnie McGrath, Janet Hammond, Victoria Wirtz, Steven Arkin, Johnny Mahlangu, Eunhee Hwang, John G. Teeter, Pengling Sun, Michael Wang and Jun Su and has published in prestigious journals such as Annals of Oncology, British Journal of Haematology and Journal of Thrombosis and Haemostasis.

In The Last Decade

Daniel R Malan

6 papers receiving 207 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel R Malan South Africa	5	122	94	79	60	27	7	221
Mindy Smith United States	7	140 1.1×	193 2.1×	46 0.6×	57 0.9×	12 0.4×	10	309
Milagros González‐Rivera Spain	5	65 0.5×	29 0.3×	31 0.4×	7 0.1×	9 0.3×	5	134
Eduardo Rodríguez‐Arbolí Spain	7	29 0.2×	10 0.1×	92 1.2×	56 0.9×	14 0.5×	28	163
V. Jubault France	7	102 0.8×	83 0.9×	17 0.2×	74 1.2×	5 0.2×	9	222
Abigail Severn United Kingdom	6	49 0.4×	36 0.4×	35 0.4×	54 0.9×	2 0.1×	8	144
Jasmeen Dara United States	9	36 0.3×	13 0.1×	61 0.8×	8 0.1×	12 0.4×	23	166
Megan Anderson United States	7	41 0.3×	27 0.3×	19 0.2×	10 0.2×	7 0.3×	18	141
Michèle Pauchard France	7	33 0.3×	36 0.4×	37 0.5×	5 0.1×	22 0.8×	9	109
Catherine Dhiver France	8	118 1.0×	99 1.1×	6 0.1×	23 0.4×	3 0.1×	15	172
Josep M. Guardiola Spain	11	184 1.5×	79 0.8×	10 0.1×	22 0.4×	11 0.4×	25	423

Countries citing papers authored by Daniel R Malan

Since Specialization

Citations

This map shows the geographic impact of Daniel R Malan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel R Malan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel R Malan more than expected).

Fields of papers citing papers by Daniel R Malan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel R Malan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel R Malan. The network helps show where Daniel R Malan may publish in the future.

Co-authorship network of co-authors of Daniel R Malan

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel R Malan. A scholar is included among the top collaborators of Daniel R Malan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel R Malan. Daniel R Malan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Muñoz‐Couselo, Eva, Henri Montaudié, Miguel‐Ángel Berciano‐Guerrero, et al.. (2024). 1136P Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study. Annals of Oncology. 35. S745–S746. 1 indexed citations

Mahlangu, Johnny, Daniel R Malan, Silva Zupančić Šalek, et al.. (2023). Treatment with Marstacimab for People with Severe Hemophilia a or B: a Plain Language Summary of the results from a short-term study and a longer-term study. 3(4). 1 indexed citations

Mahlangu, Johnny, Daniel R Malan, Silva Zupančić Šalek, et al.. (2022). A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia. British Journal of Haematology. 200(2). 229–239. 28 indexed citations

Mahlangu, Johnny, et al.. (2022). Long‐term safety and efficacy of the anti‐tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. British Journal of Haematology. 200(2). 240–248. 43 indexed citations

Gruppo, Ralph A., Daniel R Malan, J. Kapocsi, et al.. (2018). Phase 1, single‐dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Journal of Thrombosis and Haemostasis. 16(10). 1984–1993. 17 indexed citations

Malan, Daniel R, et al.. (2010). 96-Week Efficacy and Safety of Atazanavir, With and Without Ritonavir, in a HAART Regimen in Treatment-Naive Patients. Journal of the International Association of Physicians in AIDS Care. 9(1). 34–42. 17 indexed citations

Malan, Daniel R, et al.. (2008). Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 47(2). 161–167. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact